ArticleAnnals of clinical microbiology and antimicrobials2015
Antibiotic resistance and genotype of beta-lactamase producing Escherichia coli in nosocomial infections in Cotonou, Benin.
Article in Annals of clinical microbiology and antimicrobials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 85 citations in OpenAlex.
- Extended-spectrum β-lactamase production and antimicrobial resistance among Enterobacteriaceae causing clinical infections in Africa: a systematic review and meta-analysis (2012-2020).European journal of medical research · 2025Pooled it
- Antimicrobial resistance in Africa: a systematic review.BMC infectious diseases · 2017Pooled it
- Antimicrobial Resistance Trends in Urinary Tract Infections in 6 African Countries.JAMA network open · 2026Article
- Surveillance of Healthcare-Associated Infections in the WHO African Region: Systematic Review of Literature from 2011 to 2024.Antibiotics (Basel, Switzerland) · 2025Review
- Antimicrobial resistance trends of Escherichia coli and Staphylococcus aureus isolated from clinical blood cultures in Namibia: a nine-year (2011-2019) retrospective study.BMC infectious diseases · 2025Article
- One-Day Prevalence of Extended-Spectrum β-Lactamase (ESBL) and Carbapenemase-Producing Bacteria in Fecal Samples from Surgical Patients: A Concerning Trend of Antibiotic Resistance.Infection and drug resistance · 2025Article
- Antimicrobial resistance profile and associated factors of hospital-acquired gram-negative bacterial pathogens among hospitalized patients in northeast Ethiopia.BMC microbiology · 2024Article
- Phenotypic and genotypic characterization of extended spectrum beta-lactamase producingOpen veterinary journal · 2024Article
- Prevalence, antibiotic resistance, and virulence gene profile ofVeterinary world · 2023Article
- Resistance and Biofilm Production Profile of Potential Isolated fromMicroorganisms · 2023Article
- Article
- Prevalence of Carbapenemase and Extended-Spectrum β-Lactamase ProducingAntibiotics (Basel, Switzerland) · 2023Article
- Prevalence and characterization of ESBL-producingFrontiers in public health · 2023Article
- Multidrug-Resistant and Genetic Characterization of Extended-Spectrum Beta-Lactamase-ProducingAnimals : an open access journal from MDPI · 2022Article
- Emergence of High Prevalence of Extended-Spectrum Beta-Lactamase and Carbapenemase-ProducingBioMed research international · 2022Article
- Occurrence and distribution of extended-spectrum β-lactamase in clinicalGhana medical journal · 2021Article
- Assessment of the Presence of Resistance Genes Detected from the Environment and Selected Food Products in Benin.Journal of environmental and public health · 2021Article
- Whole-Genome Sequencing-Based Antimicrobial Resistance Characterization and Phylogenomic Investigation of 19 Multidrug-Resistant and Extended-Spectrum Beta-Lactamase-PositiveFrontiers in microbiology · 2021Article
- Fluorescent Mesoporous Nanoparticles for β-Lactamase Screening Assays.ChemistryOpen · 2020Article
- The first report ofIranian journal of basic medical sciences · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBeta lactams are the most commonly used group of antimicrobials worldwide. The presence of extended-spectrum lactamases (ESBL) affects significantly the treatment of infections due to multidrug resistant strains of gram-negative bacilli. The aim of this study was to characterize the beta-lactamase resistance genes in Escherichia coli isolated from nosocomial infections in Cotonou, Benin.
methodsEscherichia coli strains were isolated from various biological samples such as urine, pus, vaginal swab, sperm, blood, spinal fluid and catheter. Isolated bacteria were submitted to eleven usual antibiotics, using disc diffusion method according to NCCLS criteria, for resistance analysis. Beta-lactamase production was determined by an acidimetric method with benzylpenicillin. Microbiological characterization of ESBL enzymes was done by double disc synergy test and the resistance genes TEM and SHV were screened by specific PCR.
resultsESBL phenotype was detected in 29 isolates (35.5%). The most active antibiotic was imipenem (96.4% as susceptibility rate) followed by ceftriaxone (58.3%) and gentamicin (54.8%). High resistance rates were observed with amoxicillin (92.8%), ampicillin (94%) and trimethoprim/sulfamethoxazole (85.7%). The genotype TEM was predominant in ESBL and non ESBL isolates with respectively 72.4% and 80%. SHV-type beta-lactamase genes occurred in 24.1% ESBL strains and in 18.1% of non ESBL isolates.
conclusionThis study revealed the presence of ESBL producing Eschericiha coli in Cotonou. It demonstrated also high resistance rate to antibiotics commonly used for infections treatment. Continuous monitoring and judicious antibiotic usage are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.